Ascendis Pharma Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Ascendis Pharma (ASND) Tops Q2 EPS by EUR 37c, Beats on Revenue; Offers FY23 Revenue Guidance
September 5, 2023 4:04 PM EDTAscendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR2.16), EUR0.37 better than the analyst estimate of (EUR2.53). Revenue for the quarter came in at EUR47.4 million versus the consensus estimate of EUR37.37 million.
GUIDANCE:
Ascendis Pharma sees FY2023 revenue... More
